IDiyas

For the Inventor, By the Inventor

Flemington, NJ, United States of America

Aleksey I Gerasyuto

LinkedIn
USPTO Granted Patents = 23 

 

Average Co-Inventor Count = 12.6

ph-index = 4

Forward Citations = 47(Granted Patents)


Company Filing History:

goldMedal15 out of 15 
 
Morphic Therapeutic, Inc.
 patents
silverMedal3 out of 183 
 
Ptc Therapeutics, Inc.
 patents
bronzeMedal3 out of 10 
 
Hibercell, Inc.
 patents
4. 1 out of 5,444 
 
University of Texas System
 patents
5. 1 out of 10 
 
Mmv Medicines for Malaria Venture
 patents
6. 1 out of 4 
 
Petra Pharma Corporation
 patents
where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...
Loading Chart...
23 patents (USPTO):
1. 12459942 - Inhibiting (α-v)(β-6) integrin (2025-11-04),
2. 12415796 - Inhibitors of (αv)(β6) integrin (2025-09-16),
3. 12221416 - Antagonists of human integrin α4β7 (2025-02-11),
4. 12145935 - Inhibitors of (α-v)(β-6) integrin (2024-11-19),
5. 11919902 - Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors (2024-03-05),
6. 11903936 - Anti-malarial agents (2024-02-20),
7. 11858941 - Heterocyclic and heteroaryl compounds for treating Huntington's disease (2024-01-02),
8. 11827621 - Inhibitors of (α-v)(β-6) integrin (2023-11-28),
9. 11795167 - Inhibitors of (α-v)(β-6) integrin (2023-10-24),
10. 11739087 - Inhibiting (α-v)(β-6) integrin (2023-08-29),
11. 11667651 - Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-06-06),
12. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2023-05-16),
13. 11584763 - Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors (2023-02-21),
14. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),
15. 11174228 - Antagonists of human integrin (α4)(β7) (2021-11-16),

Title: The Innovative Mind of Aleksey I. Gerasyuto

Introduction: Aleksey I. Gerasyuto, based in Flemington, NJ, has made significant contributions to the field of biomedical research and pharmacology. With a remarkable portfolio of 21 patents, he has played a vital role in developing novel therapeutic approaches aimed at addressing specific diseases and conditions.

Latest Patents: Gerasyuto's latest patents include groundbreaking work on antagonists of human integrin α4β7. These small molecule antagonists exhibit potential in treating various diseases by modulating the immune response. Additionally, he has developed inhibitors of αvβ6 integrin, which also focus on innovative methods for treating a range of health conditions. Both patents underscore his commitment to advancing medical science through targeted drug discovery and development.

Career Highlights: Throughout his career, Gerasyuto has collaborated with leading biopharmaceutical companies including Morphic Therapeutics, Inc. and PTC Therapeutics, Inc. His time at these organizations has allowed him to further refine his expertise in integrin biology and drug development, positioning him as a respected innovator in the industry.

Collaborations: Gerasyuto has worked closely with notable colleagues such as Fu-Yang Lin and Blaise S. Lippa. These collaborations have not only enhanced his research capabilities but have also contributed to the successful advancement of innovative therapeutic strategies and the patenting of novel inventions.

Conclusion: Aleksey I. Gerasyuto's innovative work and extensive patent portfolio reflect his dedication to advancing medical research and therapeutic innovation. By constantly developing and patenting new methods and compounds, he continues to make a substantial impact in the pharmaceutical industry, addressing unmet medical needs and opening doors for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…